Poor
Poorly Aligned
Patient Risk:
Moderate
Summary
The supplied label excerpt only states that prednisone can cause negative nitrogen balance due to protein catabolism. It does not establish the response’s blood-pressure effects, dose-specific estimates, proposed mechanisms, risk factors, interactions, or discontinuation claims.
Category Scores
Accurate Statements
Unsupported Statements
The claims that prednisone raises systolic or diastolic blood pressure by specified amounts, that effects vary with dose or duration, and that particular doses or durations correspond to stated blood-pressure changes or sustained-hypertension risks.
The supplied label excerpt does not address blood pressure or provide quantitative dose-duration estimates.
The claims about renal sodium reabsorption, volume expansion, vascular sensitivity to catecholamines or angiotensin II, peripheral resistance, and nitric-oxide-mediated vasodilation.
These mechanisms are not described in the supplied label excerpt.
The claims about increased blood glucose or cholesterol and resulting effects on vascular health.
The supplied excerpt states only that negative nitrogen balance can occur due to protein catabolism; it does not address glucose, cholesterol, or vascular health.
The claims identifying pre-existing hypertension, age over 60, renal impairment, obesity, metabolic syndrome, or concurrent diuretics or antihypertensives as modifiers of the blood-pressure response.
The supplied label excerpt does not identify these risk factors or interactions.
The claim that NSAIDs taken with prednisone can blunt blood-pressure control.
The supplied label excerpt does not address NSAID interactions or blood-pressure control.
The claims that abrupt discontinuation can cause hypotension and that tapering allows the kidneys to re-establish sodium balance.
The supplied label excerpt does not discuss discontinuation, tapering, hypotension, or sodium balance.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Moderate
The response gives numerous precise dose-response estimates and risk-factor claims that are not established by the supplied label excerpt. No direct contradiction is shown, but unsupported quantitative claims could be misleading.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Poorly Aligned
Primary Issue
The response presents detailed blood-pressure estimates, mechanisms, risk factors, and interaction claims not supported by the supplied label excerpt.
Suggested Improvement
Restrict claims to information established by the supplied label, or clearly indicate that the excerpt does not establish the stated blood-pressure effects and estimates.